Kornimate/medical-research-clean huggingface dataset:
acute kidney injury neutrophil gelatinase-associated lipocalin evaluation of symptomatic heart failure study

Conditions: Acute Decompensated Heart Failure; Acute Kidney Injury

Summary: akinesis is a clinical study to assess the utility of blood and urine ngal tests in predicting worsening kidney function in patients who present with acute heart failure (ahf) and who are treated with diuretics. it is believed that rising ngal levels in the blood and/or urine can predict acute kidney injury. it is also believed that patients who are admitted to the hospital with high ngal levels in the blood/urine will have poorer outcomes.


Eligibility criteria:
inclusion criteria: * subjects must be at least 18 years of age. * subjects must present to the hospital with one or more signs or symptoms of acute heart failure (ahf). signs and symptoms include shortness of breath from walking, rales or crackles, galloping heart rhythm, jugular venous distension, trouble breathing at rest or when lying down, waking breathless at night, using more than 2 pillows to sleep, tiring easily, swelling of feet, ankles or legs, frequent coughing, a cough that produces mucous or blood-tinged sputum, or a dry cough when lying flat. * subjects must receive iv diuretics, or there must be an intent to treat with iv diuretics. * subjects must be willing and able to comply with all aspects of the protocol. * subjects must provide signed informed consent. exclusion criteria: * subjects that present with symptoms consistent with acute coronary syndromes (ami or ua) as the chief cause of the current episode of ahf. * subjects already on dialysis prior to enrollment or if dialysis initiation is already planned during the current hospital visit. * subjects that have had any major organ transplant (heart, lung, kidney, or liver). * subjects that have participated in a drug treatment study within the past 30 days or if they have already been enrolled as a subject in this study. * women who verbally report being pregnant at the time of screening and anyone belonging to a vulnerable population that is deemed inappropriate for inclusion into the study by the irb/ec.

Keywords: acute kidney injury (aki) acute decompensated heart failure (adhf) neutrophil gelatinase associated lipocalin (ngal) biomarker
analysis of tissues from patients in trial of myo-inositol to prevent lung cancer

Conditions: AKT

Summary: this study will examine tissue specimens from patients participating in a trial of high-dose myo-inositol to prevent lung cancer. the trial, conducted at the british columbia cancer agency-vancouver cancer center (bcca-vcc), includes people who have pre-cancerous changes in the air passages of their lungs. the bcca-vcc trial was designed to determine side effects of taking large amounts of the food supplement myo-inositol for longer than a month and if the supplement can help smokers stop smoking. the current study will look at the levels of a substance called akt in tissue samples obtained from air passages of subjects in the bcca-vcc trial. akt is activated by tobacco components and can be found in lung tumor specimens and pre-cancerous lesions. myo-inositol may affect akt levels and help prevent progression of pre-cancerous lesions to cancer. people participating in the bcca-vcc phase 1 myo-inositol trial are eligible for this study. tissue samples obtained from air passages of these patients during their participation in that study will be sent to the national cancer institute for analysis of akt levels.

human transbronchial biopsy specimens collected under protocol study numbers cdr0000302633; bcca-u98-0411; bcca-c02-0298 will be immunohistochemically stained for activated akt using phospho-specific antibodies. these samples are part of a phase i chemoprevention trial of myo-inositol being conducted in vancouver, bc by the british columbia cancer agency in collaboration with the national cancer institute (nci). the transbronchial specimens will be sent to the nci for analysis of activated akt. the study aims to determine whether myo-inositol, a putative inhibitor of the upstream kinase phosphatidylinositol 3-kinase, can alter activated akt levels in smokers with bronchial dysplasia.

Eligibility criteria:
* inclusion criteria: any patients entered into phase 1 myo-inositol trial are eligible for inclusion, provided that they have consented to tissue analysis in the original consent form. exclusion criteria: none anticipated at this time.

Keywords: akt immunohistochemistry myoinositol bronchial specimens phosphorylation
the effect of transcatheter ventricular septal defect closure on heart rate variability parameters

Conditions: Ventricular Septal Defect; Closure; Interventricular Septum; Autonomic Nervous System Imbalance

Summary: in this study; we evaluated the heart rate variability parameters of pediatric patients whose vsds were closed with the transcatheter method before and after, and compared with the control group.

heart rate variability (hrv) is a sign of cardiac autonomic nervous system. evaluation of hrv in pediatric ventricular septal defect (vsd) cases before and after transcatheter closure will enlighten us in terms of cardiac autonomic control. methods: 19 vsd cases treated with transcatheter closure method and 18 healthy children were enrolled in the study. 24 hours holter rhythm monitorization was applied to all patients before closure of vsd and to the control group. in the patient group, holter rhythm monitorization was repeated in the third months. hrv parameters were obtained from cardio scan premier 12® program. frequency domain (total power, vlf, lf, hf, lf/hf ratio) and time domain analysis (sdnn, sdann, sdnni, pnn50, rmssd) were applied.

Eligibility criteria:
inclusion criteria: * vsd diameter \<6mm * significant left-to-right shunt * left atrial and ventricular enlargement detected by echocardiography or calculation of qp/qs ratio above 1.5 in the catheterization laboratory (qp/qs\>1.5) exclusion criteria: * patients with arrhythmia after the procedure * young patients who may be inconsistent during holter records

Keywords: ventricular septal defect heart rate variability percutaneous vsd closure
effect of intraventricular tpa following aneurysmal subarachnoid hemorrhage

Conditions: Subarachnoid Hemorrhage; Cerebral Vasospasm; Cerebral Aneurysm; Hydrocephalus

Summary: this study will evaluate the hypothesis that the administration of intraventricular tpa reduces the rates of cerebral vasospasm and ventriculoperitoneal shunt-dependent hydrocephalus in patients with aneurysmal subarachnoid hemorrhage.


Eligibility criteria:
inclusion criteria: * age greater than 18 years old. * sah due to aneurysm, as determined by ct angiogram or cerebral angiogram. * modified fisher (mf) grade 3 or 4 sah, defined as thick cisternal blood without (grade 3) or with (grade 4) intraventrciular blood. * exclusion of the aneurysm from the parent circulation by endovascular embolization (raymond class i or ii) within 48 hours of ictus. * ventriculostomy placement must occur prior to randomization. * informed consent obtained from the patient or patient's decision maker exclusion criteria: * determination by treating physician(s) that no ventriculostomy is needed. * presence of intrinsic clotting disorders (e.g. due to hepatic failure, nephrotic syndrome, etc). subjects whose pharmacologic anticoagulation is reversed, as determined by pt/inr, ptt within our institution's normal range, will be permitted to participate in this study. * presence of significant anemia, defined as hemoglobin \< 8 gm/dl. * patients who undergo endovascular techniques requiring post-operative dual anti-platelet therapy. * residual aneurysm sac filling (raymond class iii occlusion). * aneurysm or vessel perforation during the endovascular procedure. * presence of craniectomy. * significant neurologic disability prior to the onset of sah. * determination that administration of tpa/placebo cannot be initiated within 72 hours of symptom onset. * presence of untreated intracranial aneurysms larger than 3mm on ct angiography or cerebral angiogram.
efficacy and safety of hetrombopag in non-severe aplastic anemia

Conditions: Aplastic Anemia; Drug Effect

Summary: this is a prospective one arm study to explore the efficacy and safety of hetrombopag in non-severe aplastic anemia. patients meeting the inclusion and exclusion criteria would be recruited. treatment of hetrombopag would be started with 5mg/day. the dosage would be increased by 2.5mg/day every 2 weeks if the platelet count remains less than 20×10e9/l and reduced if the platelet count reaches over than 150×10e9/l. the maximum dosage is 15mg/day. all patients would receive treatment for at least 6 months except that the platelet \<20×10e9/l at the dosage of 15mg/day for 4 weeks or the platelet ≥200×10e9/l at the dosage of 5mg/week for 2 weeks. the hematological response rate and safety will be recorded and compared at d15, 1month, 1.5month, 2month, 3month, 4month, 5month, 6month, 8month, 10month and 1year.


Eligibility criteria:
inclusion criteria: 1. patients diagnosed to be non-severe aplastic anemia 2. patients with platelet count \< 30×109/l and have at least one of the followings: ①absolute neutrophil count \< 1.5×109/l, ②platelet count \< 50×109/l, ③ hemoglobin level \< 100g/l 3. patients have no response or relapsed following at least one treatment course in a period time of \> 6 months of immunosuppression containing csa or csa+anti-thymocyte globulin (atg); 4. eastern cooperative oncology group (ecog) performance status 0-2; 5. patients able to understand and comply with protocol requirements and instructions and have signed and dated informed consent. exclusion criteria: 1. congenital aplastic anemia; 2. presence of chromosomal aberration; 3. evidence of a clonal hematologic bone marrow disorder (mds, aml) on cytogenetics; 4. presence with pnh clone ≥50%; 5. patients received hsct before; 6. uncontrolled infection or bleeding with standard treatment; 7. allergic to hetrombopag or accessories; 8. hiv, hcv or hbv active infection or liver cirrhosis or portal hypertension; 9. patient with qtcf (fridericia's qt correction formula) at screening \ 180/100mmhg)，pulmonary artery hypertension; 10. have any concomitant malignancies within 5 years expect for local basal cell carcinoma of the skin; 11. past history of thromboembolic event, heart attack or stroke (including anti-phospholipid antibody syndrome) and current use of anticoagulants; 12. pregnant or nursing (lactating) woman; 13. have attended other clinical trials within 3 months;
a study of pemetrexed in children with recurrent cancer

Conditions: Osteosarcoma; Medulloblastoma; Sarcoma, Ewing's; Neuroblastoma (Measurable Disease); Neuroblastoma (Metaiodobenzylguanidine; Positive Evaluable); Rhabdomyosarcoma; Ependymoma; Non-brainstem High-grade Glioma

Summary: to determine the response rate of pemetrexed given every 21 days for the treatment of children with relapsed or refractory osteosarcoma, ewing's sarcoma/peripheral primitive neuroectodermal tumors (pnet), rhabdomyosarcoma, neuroblastoma, ependymoma, medulloblastoma/supratentorial pnet or non-brain stem high-grade glioma.


Eligibility criteria:
inclusion criteria: * patients must have osteosarcoma, ewing's sarcoma, medulloblastoma, neuroblastoma, rhabdomyosarcoma, ependymoma or high-grade non-brainstem glioma * measurable disease * eastern cooperative oncology group (ecog) performance 0,1,2 * adequate renal, liver and bone marrow function * patient's current disease state must be one with no known curative therapy or therapy proven to prolong survival with an acceptable quality of life exclusion criteria: * growth factors that support platelet or white cell number or function must not have been administered within the last 7 days prior to enrollment (14 days if neulasta) * patients with central nervous system (cns) tumors who have not been on a stable or decreasing dose of dexamethasone or other corticosteroid for 7 days prior to enrollment * patients with uncontrolled infection * patients who have received pemetrexed previously * patients with pleural effusions or ascites
schroth exercise versus functional electrical stimulation in adolescent with spinal deformities

Conditions: Idiopathic Spinal Deformities

Summary: abnormal spinal curvature can occur as a result of neurologic, orthopedic or idiopathic factors. the role of physiotherapy is not only to prevent intrinsic changes that may occur in the spine but also be used to correct postural abnormalities. this study will investigate the impact of schroth exercise compared to functional electrical stimulation in adolescent with spinal deformities (scoliosis and or kyphosis).


Eligibility criteria:
inclusion criteria: * children in this group will be healthy category according to cdc (centers for disease control and prevention) growth chart which ranged from bmi-for-age 5th to 85th percentiles . * all children are normal \&perform all activities of daily living * they were able to understand and follow verbal commands and instructions included in the testing procedures. exclusion criteria: * all of them could be part of recreational activities in their public schools but no competitive sports. * children who participated in any regular sport activities involving the lower extremities will be excluded. * none of them had any surgical intervention . * none of them had any history of other musculoskeletal deformities or neuromuscular disorders. * they had neither visual, auditory defect.
prospective quality register of patients with confirmed covid-19 at oslo university hospital

Conditions: COVID-19

Summary: covid-19 is a recently emerging infectious disease with a very large impact on health care world-wide. the disease is still poorly described. it is an urgent need for better clinical characteristics. a prospective, quality register is therefore established for increasing the knowledge about the disease, the covid patients and the prognosis.

all patient hospitalized at oslo university hospital, ullevål, is prospectively registered in the approved quality register. background, clinical and paraclinical data is harvested and registered, as well as treatment and mortality.

Eligibility criteria:
inclusion criteria: * confirmed covid-19 * hospitalized exclusion criteria: * none
study of neoantigen mrna vaccines in patients with resectable pancreatic cancer

Conditions: Pancreatic Cancer

Summary: the purpose of this study is to evaluate the safety and efficacy of treating pancreatic cancer with surgery to remove cancerour tissue, followed by camrelizumab and a personalized cancer mrna vaccines.

the first purpose of this study is to evaluate the safety of treating pancreatic cancer with surgery to remove cancerour tissue. following with camrelizumab and a personalized neoantigen mrna vaccines, and then with chemotherapy.

Eligibility criteria:
inclusion criteria: * subjects voluntarily participate in this clinical study and sign the informed consent form (icf). * subjects must be \>/= 18 years of age at time of informed consent. * subjective with radiographically resectable primary pancreatic tumors with radiographic features consistent with adenocarcinoma will be evaluated for surgical resection. * subjects with histologically confirmed resected ductal pancreatic adenocarcinoma with macroscopic complete resection (r0 and r1) will be selected for neoantigen vaccine creation. * performance status of 0 or 1 on eastern cooperative oncology group (ecog). * subjects must not have had prior chemotherapy, radiation therapy, or immunotherapy for pancreatic ductal adenocarcinoma（pdac）. * subjects with estimated survival \> 12 weeks. exclusion criteria: * prior neoadjuvant treatment, radiation therapy, anti-pd-1 antibody or any other immune therapy for pancreatic ductal adenocarcinoma. * known hypersensitivity or allergy to the active substance or to any of the excipients of sj-neo006, camrelizumab, gemcitabine, abraxane. * actie, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy, defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment. * known infection with hepatitis b or c, or history of human immunodeficiency virus (hiv) infection or subjects receiving immunosuppressive or myelosuppressive medications that would, in the opinion of the investigator, increase the risk of serious neutropenic complications. * pregnancy, breastfeeding, or intending to become pregnant during the study or within 90 days after the last dose of study treatment. * new york heart association (nyha) class iii-iv heart failure, uncontrolled hypertension, clinically significant cardiac dysthythmia, or electrocardiogram abnormality, cerebrovascular accident, transient ischemic attack, or seizure disorder. * history or autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease. * any situation judged by the investigators that may increase the risk of the subjects or interfere with the clinical trial outcome.

Keywords: mrna vaccine
evaluation of safety and efficacy in bey1107 in monotherapy gemcitabine combination in patient with pancreatic cancer

Conditions: Locally Advanced or Metastatic Pancreatic Cancer

Summary: this study is a single center, open-label, non-comparative, phase i/ii clinical trial to assess the maximum tolerated dose (mtd), safety and efficacy of bey1107 in monotherapy and in combination with gemcitabine in patient with locally advanced or metastatic pancreatic cancer.

the key purpose of the main part of the study is to assess the mtd, safety and efficacy of bey1107 as monotherapy and combination therapy for locally advanced and/or metastatic pancreatic cancer. the main purpose of the safety lead-in (dose-finding) part of the study is to determine the safety and tolerability of bey1107, to determine the mtd. patient will receive bey1107 for 4 weeks in monotherapy for each cohort (administered in a 3-weeks-on / 1-week-off) during phase i-1 trial. at next stage, patient will receive bey1107 with gemcitabine for 4weeks in phase i-2 trial. final stage, patient will receive bey1107 with gemcitabine for 24weeks in phase ii trial. blood samples will be collected for safety, pharmacokinetic and biomarker analysis. archival of fresh biopsy tissue will also be collected for biomarker analysis.

Eligibility criteria:
inclusion criteria : 1. histologically or cytologically confirmed with pancreatic ductal adenocarcinoma or undifferentiated carcinoma of the pancreas 2. at lease one measurable lesion according to recist v.1.1 3. eastern cooperative oncology group (ecog) 0,1 or 2 4. over 12 weeks of life expectancy 5. adequate bone marrow, renal and liver function at screening exclusion criteria : 1. a patient who has treatment history with locally advanced and/or metastatic pancreatic cancer 2. major surgery history at screening 3. uncontrolled brain metastasis evidence 4. active bacterial infection patients 5. malignant tumor other than basal cell carcinoma, cervix carcinoma in situ and papillary thyroid cancer 6. expected pregnant or breast-feeding patients 7. hiv, active hepatitis b or c infection 8. a patient who has hypersensitivity with bey1107 or gemcitabine

Keywords: pancreatic cancer
low-intensity exercise in metabolic syndrome

Conditions: Metabolic Syndrome; Obesity; Hypertension; Hyperlipidemias; Glucose Metabolism Disorders

Summary: people with metabolic syndrome (mets) are characterized by a lower quality of life in terms of reduced vital activity, emotional state, and social functioning. therefore, the investigator's aim was to determine the impact of low-intensity exercise and psychoeducation on depression symptoms and self-perceived stress in women with mets.

metabolic syndrome (mets) is currently one of the major threats to health in highly developed societies. a recent study has demonstrated that depression may be significantly associated with mets in people aged 60 years or over. the more components of mets that are evident in the individual, the more depressive symptoms this individual is likely to exhibit. mets treatment is essentially founded on implementing lifestyle changes which involve regular physical activity and healthy dietary habits. systematically undertaking exercise has a beneficial influence on health, particularly on cardiovascular system functions as well as the quality of life and depression status in middle-aged and older women with mets. previous work has shown moderate or high intensity exercise to be optimal for the treatment of mets. nevertheless, many patients with mets have hypertension and obesity. therefore, for safety reasons, the patient's condition during intensive group exercises should be constantly monitored by a physician or specialized equipment, which generates costs and may limit the availability of this type of intervention. hence, the investigator's aim was to determine the impact of 12 weeks of low-intensity exercise, combined with psychoeducation, on the severity of depression symptoms and self-perceived stress in women with mets.

Eligibility criteria:
inclusion criteria: the presence of metabolic syndrome diagnosed using the international diabetes federation-recommended criteria (2006): * "mandatory" central obesity (defined as waist circumference ≥ 80 cm in females), and any two of the following: * raised triglycerides (\>150 mg/dl), * reduced hdl cholesterol (50 mg/dl in females), * elevated blood pressure (bp; systolic bp \> 130 or diastolic bp \> 85 mm hg) , * increased fasting plasma glucose (\>100 mg/dl), exclusion criteria: * disturbed cognitive functions (mini-mental state examination \> 23), * the inability to move independently or a motor disability precluding exercise, * serious neurological or orthopaedic conditions (e.g., advanced parkinson's disease, severe stroke consequences), * attending fewer than 13 intervention sessions.

Keywords: metabolic syndrome low-intensity exercise mental health depression stress physical activity women